Search
Gemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalMarketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered … On September 1 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule
Piperazine
go.drugbank.com/drugs/DB00592ApprovedVet approvedWithdrawnOutside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. … Piperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism.
Elapegademase
go.drugbank.com/drugs/DB14712Approved[F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]
Synonyms: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH, THREONINE (A>T))BOS TAURUS ADENOSINE DEAMINASE (BOVINE ADENOSINE AMINOHYDROLASE, EC=3.5.4.4)-(1-356)-PEPTIDE PRODUCED IN ESCHERICHIA COLI, AN AVERAGE OF 13 RESIDUES ARE SUBSTITUTED ON N.ALPHA..1ALANINE AND N6Berdazimer
go.drugbank.com/drugs/DB18712ApprovedIt releases NO through exposure to proton donors like water, which will degrade the N-diazeniumdiolate entity. … Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors.
Ergoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [T90] The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives
Domperidone
go.drugbank.com/drugs/DB01184ApprovedInvestigationalVet approvedA specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Products: Nu-domperidone 10 Mg TabletsRecombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
alpha-Tocopherol succinate
go.drugbank.com/drugs/DB14001ApprovedNutraceuticalVet approvedAlpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements. … Most individuals obtain adequate vitamin E intake from their diets; genuine vitamin E deficiency is considered to be rare.
Mixtures: Ni-C-E-LE Plus, Dry Form Vitamin E 400iu With Selenium 100mcgPegzilarginase
go.drugbank.com/drugs/DB14780Approved[A275423,L56053] Pegzilarginase-nbln received accelerated approval from the U.S. … [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the
Potassium gluconate
go.drugbank.com/drugs/DB13620ApprovedIn dietary supplements, potassium is often present as potassium chloride, but many other forms—including potassium citrate, phosphate, aspartate, bicarbonate, and **gluconate**—are also used [L2652]. … Potassium gluconate is a salt of [DB01345] and is classified as a food additive by the FDA [L2654]. It is also used as a potassium supplement [L2657]. Potassium is an essential nutrient.
Mixtures: Cal-mag Plus K, Mn and Zn Caplets